{"id":"NCT03461211","sponsor":"Amgen","briefTitle":"Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study","officialTitle":"Multicenter, Safety and Efficacy, Open-Label Extension Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Thyroid Eye Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-04-16","primaryCompletion":"2020-06-08","completion":"2021-02-17","firstPosted":"2018-03-09","resultsPosted":"2021-07-19","lastUpdate":"2024-06-28"},"enrollment":51,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Thyroid Eye Disease"],"interventions":[{"type":"BIOLOGICAL","name":"Teprotumumab","otherNames":["HZN-001"]}],"arms":[{"label":"Teprotumumab","type":"EXPERIMENTAL"}],"summary":"The overall objective is to evaluate the safety and efficacy of teprotumumab in the treatment of thyroid eye disease (TED) in participants who participated in the lead-in study HZNP-TEP-301 (NCT03298867; OPTIC) and who were either proptosis non-responders at Week 24 of HZNP-TEP-301 or were proptosis responders at Week 24 but met the criteria for re-treatment due to relapse during the Follow-Up Period of HZNP-TEP-301.","primaryOutcome":{"measure":"Percentage of Participants With a â‰¥ 2 mm Reduction From Baseline in the Study Eye Without Deterioration of Proptosis in the Fellow Eye at Week 24","timeFrame":"Baseline, Week 24","effectByArm":[{"arm":"Teprotumumab (OPTIC Placebo)","deltaMin":89.2,"sd":null},{"arm":"Teprotumumab (OPTIC Teprotumumab)","deltaMin":53.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":2},"locations":{"siteCount":13,"countries":["United States","Germany","Italy"]},"refs":{"pmids":["33768488"],"seeAlso":["http://www.TEPEZZA.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":37},"commonTop":["Muscle Spasms","Onychoclasis","Diarrhoea","Alopecia","Dry Skin"]}}